These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 24770864)
1. YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin. Khan MI; Adhami VM; Lall RK; Sechi M; Joshi DC; Haidar OM; Syed DN; Siddiqui IA; Chiu SY; Mukhtar H Oncotarget; 2014 May; 5(9):2462-74. PubMed ID: 24770864 [TBL] [Abstract][Full Text] [Related]
2. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis. Hu S; Duan YX; Zhou Q; Wang Y; Lu Q IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986 [TBL] [Abstract][Full Text] [Related]
3. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4. Lan X; Lu G; Yuan C; Mao S; Jiang W; Chen Y; Jin X; Xia Q J Cancer Res Clin Oncol; 2016 Jan; 142(1):177-85. PubMed ID: 26206483 [TBL] [Abstract][Full Text] [Related]
4. Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models. Sechi M; Lall RK; Afolabi SO; Singh A; Joshi DC; Chiu SY; Mukhtar H; Syed DN Sci Rep; 2018 Oct; 8(1):15726. PubMed ID: 30356079 [TBL] [Abstract][Full Text] [Related]
5. Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells. Liao LZ; Chen CT; Li NC; Lin LC; Huang BS; Chang YH; Chow LP Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379356 [TBL] [Abstract][Full Text] [Related]
6. Quercetin modulates Wnt signaling components in prostate cancer cell line by inhibiting cell viability, migration, and metastases. Baruah MM; Khandwekar AP; Sharma N Tumour Biol; 2016 Oct; 37(10):14025-14034. PubMed ID: 27495232 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer. Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058 [TBL] [Abstract][Full Text] [Related]
8. Cripto-1 promotes epithelial-mesenchymal transition in prostate cancer via Wnt/β-catenin signaling. Liu Y; Qin Z; Yang K; Liu R; Xu Y Oncol Rep; 2017 Mar; 37(3):1521-1528. PubMed ID: 28098905 [TBL] [Abstract][Full Text] [Related]
9. Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer. Gunasekaran VP; Nishi K; Sivakumar D; Sivaraman T; Mathan G Eur J Pharm Sci; 2018 Apr; 116():2-14. PubMed ID: 28916481 [TBL] [Abstract][Full Text] [Related]
10. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression. Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422 [TBL] [Abstract][Full Text] [Related]
11. Significances of contactin-1 expression in human gastric cancer and knockdown of contactin-1 expression inhibits invasion and metastasis of MKN45 gastric cancer cells. Chen DH; Yu JW; Wu JG; Wang SL; Jiang BJ J Cancer Res Clin Oncol; 2015 Dec; 141(12):2109-20. PubMed ID: 25952582 [TBL] [Abstract][Full Text] [Related]
12. The YB-1/EZH2/amphiregulin signaling axis mediates LPA-induced breast cancer cell invasion. Cho KH; Jeong BY; Park CG; Lee HY Arch Pharm Res; 2019 Jun; 42(6):519-530. PubMed ID: 31004257 [TBL] [Abstract][Full Text] [Related]
13. Targeting the SPOCK1-snail/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis. Chien MH; Lin YW; Wen YC; Yang YC; Hsiao M; Chang JL; Huang HC; Lee WJ J Exp Clin Cancer Res; 2019 Jun; 38(1):246. PubMed ID: 31182131 [TBL] [Abstract][Full Text] [Related]
14. The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Bommert KS; Effenberger M; Leich E; Küspert M; Murphy D; Langer C; Moll R; Janz S; Mottok A; Weissbach S; Rosenwald A; Bargou R; Bommert K Leukemia; 2013 Feb; 27(2):441-50. PubMed ID: 22772059 [TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis. Zhou QX; Jiang XM; Wang ZD; Li CL; Cui YF Med Oncol; 2015 Apr; 32(4):105. PubMed ID: 25744243 [TBL] [Abstract][Full Text] [Related]
16. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression. Imada K; Shiota M; Kohashi K; Kuroiwa K; Song Y; Sugimoto M; Naito S; Oda Y Clin Cancer Res; 2013 Sep; 19(17):4638-50. PubMed ID: 23838318 [TBL] [Abstract][Full Text] [Related]
17. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer. Jin Y; Cui Z; Li X; Jin X; Peng J Oncotarget; 2017 Apr; 8(16):26090-26099. PubMed ID: 28212533 [TBL] [Abstract][Full Text] [Related]
18. OCT4 regulates epithelial-mesenchymal transition and its knockdown inhibits colorectal cancer cell migration and invasion. Dai X; Ge J; Wang X; Qian X; Zhang C; Li X Oncol Rep; 2013 Jan; 29(1):155-60. PubMed ID: 23076549 [TBL] [Abstract][Full Text] [Related]
19. YB-1 overexpression promotes a TGF-β1-induced epithelial-mesenchymal transition via Akt activation. Ha B; Lee EB; Cui J; Kim Y; Jang HH Biochem Biophys Res Commun; 2015 Mar; 458(2):347-51. PubMed ID: 25645014 [TBL] [Abstract][Full Text] [Related]
20. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]